2023 Sustainability Highlights
Conference call for investors and analysts
March 2024
Forward-looking statements
In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failure to obtain, defend and enforce effective IP protection and IP challenges by third parties; the impact of competitive pressures including expiry or loss of IP rights, and generic competition; the impact of price controls and reductions; the impact of economic, regulatory and political pressures; the impact of uncertainty and volatility in relation to the UK's exit from the EU; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology, data protection or cybercrime; the risk of failure of critical processes; any expected gains from productivity initiatives are uncertain; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to adhere to applicable laws, rules and regulations; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; the risk of failure to adhere to increasingly stringent anti-bribery and anti-corruption legislation; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group's financial position; and the impact that the COVID-19 global pandemic may have or continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.
2 | March 2024 |
Sustainability
at AstraZeneca
Pam Cheng
E X E C U T I V E | V I C E P R E S I D E N T, G L O B A L |
O P E R AT I O N S , I N F O R M AT I O N T E C H N O L O G Y | |
A N D C H I E F | S U S TA I N A B I L I T Y O F F I C E R |
Sustainability Governance at AstraZeneca
Board of Directors - Delegated Committees | ||||||||
Board Audit Committee | Sustainability Committee | Remuneration Committee | ||||||
Philip Broadley | Nazneen Rahman | Sheri McCoy | ||||||
Senior Independent Non-Executive Director of the Board, | Non-Executive Director of the Board, | Non-Executive Director of the Board, | ||||||
Chair of the Audit Committee | Chair of the Sustainability Committee | Chair of the Remuneration Committee | ||||||
Sheri McCoy | Sheri McCoy | Nazneen Rahman | ||||||
Non-Executive Director of the Board | Non-Executive Director of the Board | Non-Executive Director of the Board | ||||||
Deborah DiSanzo | Marcus Wallenberg | Philip Broadley | ||||||
Non-Executive Director of the Board | Non-Executive Director of the Board | Senior Independent Non-Executive Director of the Board | ||||||
Anna Manz | Andreas Rummelt | |||||||
Non-Executive Director of the Board | Non-Executive Director of the Board | |||||||
Senior Executive Team (SET) | Pam Cheng | Jeff Pott | ||||||
Pascal Soriot | ||||||||
Executive Vice President, Global Operations, | Chief Human Resources Officer, Chief Compliance Officer | |||||||
Executive Director and Chief Executive Officer | ||||||||
Information Technology and Chief Sustainability Officer | and General Counsel | |||||||
Sustainability Steering Committee | ||||||||
Sustainability | Compliance | Procurement | Communications | Legal | Finance | Human Resources | Supply Chain | Health Equity |
March 2024
SET = Senior Executive Team.
2023 Sustainability highlights
Progress on our overall strategy includes:
15
public and private sector organisations convened by AstraZeneca CEO through the SMI to accelerate transition to net- zero health systems
87%
Access to Healthcare Environmental Protection Ethics and Transparency
127,384 | 67.6% | 50.1% |
healthcare workers and others trained1 | reduction in Scope 1 and Scope 2 | senior middle management roles |
(cumulative) | greenhouse gas emissions | held by women |
By 2025: 170,000 | By 2026: 98% from 2015 base year | By 2025: reach gender equality in |
management positions | ||
>66.4m | 19.5% | 11 countries |
of employee survey respondents say that they understand their contributions to our sustainability priorities
25/27
of sustainability targets in Sustainability Data Annex are "on plan"
people reached through Access to Healthcare programmes (cumulative)1
By 2025: 50m
>13.6m
people reached through our patient assistance programmes (cumulative)
reduction in our water use | with supplier diversity programmes |
By 2025: 20% below 2015 baseline | By 2025: 10 new countries outside of the US |
13.2% | 83% |
reduction in our waste | of employee survey respondents feel we |
By 2025: 10% below 2015 baseline | have a "speak up" culture |
5 1. From our philanthropic programmes including; Healthy Heart Africa and Young Health Programme. | March 2024 |
CEO = Chief Executive Officer; SMI = Sustainable Markets Initiative.
Access to Healthcare
Securing a future of access to affordable, sustainable, and innovative healthcare
Our ambition:
to promote prevention, increase
access to life-saving treatments
and strengthen global healthcare
resilience and sustainability
Our focus:
Progress in 2023
66.4m People reached1
127.3k | Healthcare workers | |
trained1 | ||
TARGETS:
50m
by2025
170k
by2025
Strategy update
Broadening beyond
philanthropic programmes for new
HEALTH EQUITY strategy
COMPREHENSIVE STRATEGY
from science to delivery of care
Innovating
Partnering
Transforming
Access to Healthcare
programmes include:
HealthyLung
YoungHealthProgramme | |
Metric"ON PLAN" | MetricACHIEVED |
Implementing
END-to-END SOLUTIONS
across entire value chain
Further detail on Health Equity
strategy later in 2024
6 | March 2024 |
1. From our philanthropic programmes including; Healthy Heart Africa and Young Health Programme.
Access to Healthcare
Partnering to drive focused interventions and policy change
Partnership for Health System Sustainability and Resilience (PHSSR)
Access in Action: PHSSR impact case studies
Committed to collaborating across SECTORS and BORDERS
Building more
SUSTAINABLE and
RESILIENT health systems
Co-founded by:
European Union
Acting Early on NCDs
launched at European Parliament
Focus:
- Data and analytics
- Prevention and early intervention
- Innovative technologies and solutions
Japan
Digital solutions
developed a digital platform for collecting and sharing medical information
Platform supporting:
- Guideline-basedtherapeutic decisions
- Detection of patients at early stages of their diseases
Brazil
Primary and community-based care
identifying financial mechanisms to:
- Strengthen primary care
- Improve community- based disease management services
Improving global health by building more sustainable and resilient health systems
7 | March 2024 |
PHSSR = Partnership for Health System Sustainability and Resilience; NCD = non-communicable disease.
Access to Healthcare - Clinical Trial Diversity
Committed to designing clinical trials with equity at the forefront
Focused on:
PATIENT CENTRICITY
DATA DRIVEN approach
SCIENCE-LEDexecution
Progress in 2023
PUBLICATION
including retrospective analysis of 246 clinical trials in the US
Launch of internal
CTD DASHBOARD
MONITORING CTD in the US
real-time tracking of for all recruiting Phase III trials1
Committed to:
Designing
INCLUSIVE TRIALS
Optimising
RECRUITMENT and
RETENTION of UREs
Improving
TRIAL DIVERSITY
8 1. Current real-time tracking of race and ethnicity for all recruiting Phase III trials sponsored by AstraZeneca with plans to expand to include age and sex in 2024. | March 2024 |
CTD = clinical trial diversity; FDA = US Food and Drug Administration; URE = under-represented ethnicities. |
Environmental Protection
Driving bold decarbonisation through Ambition Zero Carbon
Scope 1 | Scope 2 |
Scope 1 & 2
TARGETS:
Total Revenue vs. Scope 1 & 2 emissions
Scope 3 | Scope 3 |
TARGETS: |
68%
35%
103%
95%
Reduce Scope 1 & 2 emissions vs. 2015
Transition to electric vehicles
Increase energy
productivity vs. 2015
Increase
renewable electricity consumption vs. 2015
98%
by2026
100%
by20251
200%
by2025
100%
from2025
Revenue($m) | $50,000 | 700,000 | Emissions2 (tCO2e) | |
$20,000 | 300,000 | |||
$45,000 | 600,000 | |||
$40,000 | 500,000 | |||
$35,000 | ||||
$30,000 | ||||
400,000 | ||||
Total | $25,000 | &1Scope | ||
$15,000 | 200,000 | |||
$10,000 | ||||
100,000 | ||||
$5,000 | ||||
$- | - | |||
Revenue ($m)
Scope 1 & 2 (tCO2e)
SBTi Default Pathway (tCO2e)
60% | Of suppliers with | 20251 | |||
science-based targets | |||||
Launch next-generation | Byendof | ||||
2025 | |||||
near-zero GWP inhaler | |||||
Scope 3: strategic emissions approach
Metric"ON PLAN"
9 1. By 2025, 95% of our suppliers by spend covering purchased goods and services and capital goods, and 50% of our suppliers by spend covering upstream transportation and distribution and business travel, will have SBTs. | March 2024 |
tCO2e = tonnes of carbon dioxide equivalent; SBTi = Science Based Targets Initiative; GWP = Global Warming Potential. |
Biodiversity at AstraZeneca
Integrating a circular economy approach across our value chain
Circular economy
Incorporate principles of the | ||||||||
circulate economy | ||||||||
Minimise | ||||||||
Develop | ||||||||
suitable | amount of | |||||||
metrics | materials | |||||||
Increase reused | ||||||||
Maximise | ||||||||
or recycled | ||||||||
waste recycled | ||||||||
content | ||||||||
Regenerate | ||||||||
nature | ||||||||
Biodiversity
bringing nature more prominently into decision-making
By END of 2024:
Develop framework of biodiversity with
RISKS and DEPENDENCIES
Developing
TARGETS and METRICS
according to SBTN
Supporting:
AZ Forest
maximising the co-benefits of reforestation
TARGETS: | |||||
20m | Trees planted and | 200m | |||
maintained since 2020 | by2030 | ||||
Reforestation
designed to:
- Foster biodiversity
- Support sustainable livelihoods
- Build local climate resilience
Metric"ON PLAN"
10 | March 2024 |
SBTN = Science Based Targets Network.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
AstraZeneca plc published this content on 22 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 March 2024 16:40:20 UTC.